Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 5,058 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Parkinson's Disease (PD), Deep Brain Stimulation
Interventions: buntanetap/posiphen; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 25 more

Conditions: Healthy, Halitosis
Interventions: Aquamin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Renal Failure
Interventions: LCP-Tacro, Prograf; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pharmacokinetic Assessments in Healthy Volunteers
Interventions: PPI-668 capsule, PPI-668 tablet; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cystic Fibrosis
Interventions: Docosahexanoic Acid Supplement, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 6 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Hair Health, Hair Loss
Interventions: Hair Nutra Growth Supplement & Hair Nutra Boost Supplement, Hair Nutra Growth; Dietary Supplement
Lead sponsor: BrandiZone; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Cachexia
Interventions: GSK2849466, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Oxidative Stress, Dyslipidemias
Interventions: Octacosanol, Placebo; Dietary Supplement
Lead sponsor: Kosin University; Other
Eligibility: 17 Years to 19 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Epilepsy, Seizures, Epileptic
Interventions: SPN-817; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions: TT-10, TT-4; Drug
Lead sponsor: Portage Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: SYX-5219 Oral Capsule; Drug
Lead sponsor: Sitryx Therapeutics Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more

Conditions: Healthy
Interventions: K-285, Indomethacin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Pirfenidone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more

Conditions: Pediatric Heart Failure
Interventions: LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Breast Cancer
Interventions: Sapanisertib, Fulvestrant, Exemestane; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more

Conditions: Obstructive Sleep Apnea
Interventions: N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy; Dietary Supplement · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Anal High Grade Squamous Intraepithelial Lesion
Interventions: Curcuminoid Capsules; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 30 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Pain, Postoperative
Interventions: diclofenac potassium (XP21L), Placebo; Drug
Lead sponsor: Xanodyne Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 4
States / cities: Austin, Texas • Houston, Texas • San Marcos, Texas + 1 more

Conditions: Diabetic Neuropathy, Painful
Interventions: AGN 203818, placebo capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

A Study of Buntanetap in Participants With PD

Effectiveness of Aquamin® in Mitigating Halitosis

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

Effects of Octacosanol During Taekwondo Training

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Safety of Anal Curcumin

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy